The appeal of green synthesis lies in what it replaces. Conventional nanoparticle production typically relies on chemical reducing agents such as sodium borohydride or hydrazine, along with organic solvents and synthetic stabilizers, many of which are toxic, expensive, and difficult to dispose of safely. Plant extracts, by contrast, contain a rich cocktail of polyphenols, flavonoids, terpenoids, and other phytochemicals that can do double duty: they reduce dissolved metal ions to metallic nanoparticles and then cap the nascent particles, preventing them from clumping together and growing out of the nanoscale. In the new study, the team turned to the leaf extract of Eucalyptus camaldulensis, the widely planted river red gum, whose leaves are already known to be a plentiful source of antioxidant compounds. By mixing a bismuth salt precursor with this aqueous extract, the researchers were able to drive the formation of metallic bismuth nanoparticles under mild conditions, with the plant’s own biomolecules serving simultaneously as reductant and stabilizer.

Once the bismuth nanoparticles had been biosynthesized, the next step was to embed them in chitosan, a biopolymer derived from chitin, the structural material of crustacean shells and fungal cell walls. Chitosan is a favorite of biomaterials researchers for good reason: it is biocompatible, biodegradable, inherently antimicrobial, and rich in amine and hydroxyl groups that readily bind metal nanoparticles. When the bismuth nanoparticles were combined with chitosan, these functional groups acted as anchoring points, producing a bismuth nanoparticle–chitosan composite, abbreviated BiNPs–CS, in which the inorganic particles are dispersed throughout the organic matrix. The synergy is deliberate. Chitosan alone fights bacteria by disrupting cell membranes through electrostatic interactions between its protonated amine groups and negatively charged bacterial surfaces, while metal nanoparticles attack through complementary mechanisms involving membrane damage and oxidative stress. Combining the two was expected to yield a material more potent than either component alone.

Characterizing such a composite requires a battery of spectroscopic and scattering techniques, and the team deployed a trio of workhorses. Ultraviolet-visible spectroscopy provided the first indication that nanoparticles had formed, as the reduction of bismuth ions alters the optical absorption profile of the solution. Fourier-transform infrared spectroscopy, or FTIR, mapped the chemical bonds involved: shifts and changes in the absorption bands associated with chitosan’s amine and hydroxyl groups served as direct evidence of interactions between the biopolymer and the bismuth nanoparticles, confirming that the two components were not merely mixed but genuinely integrated. Finally, X-ray diffraction revealed the crystalline structure of the bismuth phase within the composite, with the width of the diffraction peaks carrying information about crystallite size according to established diffraction principles.

Size control is critical in nanomaterials, because particle dimensions govern both reactivity and biological behavior. The researchers measured particle size in two independent ways: by analyzing X-ray diffraction peak broadening and by dynamic light scattering, a technique that infers hydrodynamic size from fluctuations in scattered laser light caused by Brownian motion. Both methods converged on the same conclusion. The average size of the nanoparticles in the composites remained approximately 15 nanometers, a dimension small enough to present a large surface-area-to-volume ratio, which is favorable for antimicrobial contact, yet stable enough to be handled and processed reproducibly. Agreement between the two measurement techniques strengthens confidence that the synthesis reliably produces particles in this size range rather than a broad, uncontrolled distribution.

Reproducibility, often the Achilles’ heel of plant-mediated synthesis, received careful attention. The synthesis was performed in triplicate, and the yield of recovered dried composite product was calculated for each run. The average yield came out at 79 percent, with a standard deviation of just 1.7 percent, indicating that the reaction delivers consistent output across repeated preparations. In a field where biological variability in plant extracts can cause batch-to-batch swings, this narrow spread is a meaningful result, suggesting that the eucalyptus-mediated route could plausibly be scaled or standardized for practical use.

The most consequential experiments, however, were biological. The team evaluated the antimicrobial performance of the BiNPs–CS composites against methicillin-resistant Staphylococcus aureus, the archetypal multidrug-resistant hospital pathogen, using the well diffusion method. In this assay, wells are punched into an agar plate seeded with bacteria and filled with the test material; the microbes then grow overnight while the compound diffuses outward. Wherever the material is potent enough, bacterial growth is suppressed, leaving a transparent halo called a zone of inhibition whose diameter serves as a simple, widely used proxy for antimicrobial strength. Against MRSA, the composite performed impressively. At a concentration of 40 micrograms per milliliter, the BiNPs–CS composites produced inhibition zones of up to 17 millimeters, a result the authors describe as reflecting strong antimicrobial potential.

The significance of that figure becomes clear in context. MRSA infections are notoriously difficult to treat because the bacterium has evolved resistance to beta-lactam antibiotics, including methicillin and most penicillins, and treatment options are dwindling worldwide as resistance continues to spread. Materials that can inhibit MRSA at low concentrations are therefore of intense interest, and bismuth-based nanomaterials have an established pedigree here: previous studies have reported that bismuth oxide nanoparticles, including those produced biologically by bacteria, can suppress MRSA growth. The new study extends that logic to metallic bismuth nanoparticles embedded in a chitosan matrix, synthesized entirely through a green route. The authors suggest that the antimicrobial action likely arises from the combined effects of chitosan’s membrane-disrupting chemistry and the nanoparticle-mediated mechanisms typical of metal-based nanomaterials, though the precise molecular pathway remains an active area of investigation.

Bismuth itself brings an unusual safety profile to the table. Unlike many heavy metals, bismuth compounds are famously low in toxicity for humans, a property that has earned them a century-long role in medicine, most famously in bismuth subsalicylate, the active ingredient of common stomach remedies. Bismuth-based nanoparticles and composites are already under study for therapeutic, diagnostic, biosensing, and regenerative applications, and bismuth–chitosan composites have previously been engineered for environmental tasks such as detecting toxic heavy metals in wastewater. The Punjab team’s contribution is to connect these threads: a medically benign metal, a food-safe biopolymer, a plant-based synthesis with no toxic reagents, and a demonstrably potent antimicrobial outcome.

The researchers acknowledge the Department of Chemistry at the Pakistan Institute of Engineering and Applied Sciences and Air University in Islamabad for access to characterization facilities. Looking forward, the findings delineate what the authors call a simple, eco-friendly mechanism for producing metal-based nanocomposites with potential biomedical applications. If subsequent studies confirm biocompatibility in living systems and translate the laboratory inhibition zones into functional wound dressings, coatings, or delivery vehicles, the humble eucalyptus leaf may prove to be an unlikely but effective ally in the ongoing battle against antibiotic-resistant bacteria.

The urgency behind that claim is hard to overstate. Antimicrobial resistance is now linked to millions of deaths worldwide each year, and the World Health Organization has placed carbapenem-resistant Acinetobacter baumannii at the top of its list of critical priority pathogens — a Gram-negative bacterium notorious for shrugging off nearly every drug clinicians can deploy against it. The deeper problem is architectural: most antibiotics introduced over the past half-century are chemical variations on a handful of molecular scaffolds, so bacteria that acquire resistance to one member of a family frequently resist its relatives as well. Because established drugs converge on the same targets and the same binding sites, a single resistance mechanism — an altered ribosomal protein, a methylated RNA residue, an overactive efflux pump — can neutralize entire classes at once. New chemical classes that hit old targets in genuinely new ways are therefore among the most valuable commodities in infectious-disease research, and lasso peptides, the review argues, may be exactly that.

Lasso peptides belong to the ribosomally synthesized and post-translationally modified peptides, or RiPPs — a vast family of natural products in which the starting material is made by the ribosome as a linear precursor and then sculpted by dedicated enzymes into something far more elaborate. In lasso peptides, that sculpting produces a mechanical marvel: the N-terminal segment of the chain is stitched into a closed ring through which the C-terminal tail is threaded and then trapped, creating an interlocked lasso fold. The tail is typically cinched in place by bulky amino acids acting as plugs, and in many family members an additional cross-link prevents the tail from slipping back out. The result is a compact, rigid structure with unusual resilience; lasso peptides routinely survive proteases that would dismantle ordinary peptides, as well as temperatures and pH extremes that destroy most proteins. That mechanical constraint also confers pharmacological advantages: the molecule arrives at its target pre-folded, which sharpens binding selectivity and slows chemical degradation inside living systems.

Lariocidin, produced by Paenibacillus sp. M2, is a recently discovered member of this family with an ambition that sets it apart: it is a peptide antibiotic that goes after the ribosome, the molecular factory every bacterium needs to build its proteins. Ribosome-targeting is old territory for antibiotics — aminoglycosides, tetracyclines and macrolides all work there — but lariocidin arrives with a completely different chemical body and, crucially, a different docking address. The review’s authors situate LAR within the emerging subgroup of ribosome-targeting lasso peptides and argue that the class should be treated as a platform of microbial peptide antibiotic scaffolds for future discovery rather than a one-off curiosity. Their synthesis of the evidence gathered so far describes a compound with broad antibacterial activity, an unusual binding mode and a resistance profile that, in early testing at least, looks remarkably clean. If further work confirms that profile, the implications for drug discovery could be considerable.

To understand why that matters, it helps to picture the bacterial ribosome. In bacteria it is built from two subunits: the larger 50S subunit, which catalyzes the formation of peptide bonds, and the smaller 30S subunit, which reads the genetic message. The 30S subunit is organized around 16S ribosomal RNA, the molecular scaffold of the decoding center where messenger RNA codons are checked against the anticodons of incoming aminoacyl-tRNAs, the adaptor molecules that ferry amino acids into place. Classical inhibitors exploit this machinery in well-charted ways: aminoglycosides wedge into the decoding region of 16S rRNA and trick the ribosome into misreading the genetic code, while tetracyclines physically block aminoacyl-tRNA from entering its binding site. Lariocidin does neither. According to the review, it binds a distinct site within the 30S subunit, making contacts with both 16S rRNA and aminoacyl-tRNA — a binding mode that overlaps in function but not in geography with the established drugs. Because the docking site differs, resistance mechanisms tailored to aminoglycosides or tetracyclines do not automatically extinguish lariocidin’s activity.

Functionally, the peptide delivers a double blow. First, it inhibits translocation — the ratcheting step in which the ribosome, having linked one amino acid to the growing chain, must shift the entire messenger RNA and its paired transfer RNAs by exactly one codon to make room for the next. Jam that step and protein synthesis stalls. Second, lariocidin promotes miscoding, causing incorrect amino acids to be inserted into nascent proteins. A bacterium under lariocidin attack therefore faces a pincer movement: whatever proteins it manages to finish are increasingly likely to be garbled and nonfunctional, while the overall production line grinds toward a halt. This combination of translocation inhibition and miscoding, achieved through a binding site distinct from those used by aminoglycosides and tetracyclines, forms the mechanistic heart of the review’s argument and the primary reason the authors believe cross-resistance with established ribosome-targeting antibiotics may be reduced. In an era when resistance genes circulate freely between bacterial species, an unclaimed binding site is a strategic asset.

The preclinical evidence assembled in the review is, by the sober standards of early-stage antibiotic research, encouraging. Lariocidin displays broad antibacterial activity, including against multidrug-resistant pathogens such as Acinetobacter baumannii, one of the organisms for which new therapies are most desperately needed. In laboratory assays, spontaneous resistance arises at low frequency, a sign that the ribosomal binding site cannot be trivially mutated around. Safety signals from cell-based studies are similarly promising: mammalian cytotoxicity is limited, and the peptide causes minimal hemolysis, the rupture of red blood cells that serves as a standard early warning of membrane-damaging toxicity. Most significantly, the compound has shown efficacy in mouse infection models — a hurdle many antibiotic candidates never clear, because activity in a culture dish does not guarantee that a molecule will survive, reach its target and work inside a living host. Taken together, these findings sketch a compound that is simultaneously potent, selective and demonstrably active in vivo, a combination rare enough to turn heads.

Part of the excitement lies in what the lasso scaffold itself makes possible. Because RiPPs are genetically encoded, their sequences can be edited like software: individual amino acids in the ring or the threaded tail can be swapped to tune potency, spectrum or stability, while the knot-tying biosynthetic enzymes can be repurposed for the chemoenzymatic production of analogs that would be difficult to synthesize by chemistry alone. The same genetics that make lasso peptides engineerable also make them findable. Biosynthetic gene clusters for these molecules lie scattered across bacterial genomes and metagenomic datasets, meaning computational mining of sequence databases can point researchers toward previously hidden lasso peptides before anyone has cultured the producing organism. The review frames lariocidin as a flagship for this strategy — proof that searching the microbial pan-genome for ribosome-targeting lasso peptides can surface antibiotic scaffolds with properties that conventional small-molecule screening has struggled to deliver, and a starting point for engineering next-generation derivatives.

The authors are nonetheless explicit about how far the compound still has to travel. Lariocidin remains at an early developmental stage, and several fundamental questions are unresolved. Its pharmacokinetics and pharmacodynamics — how the molecule is absorbed, distributed, broken down and cleared, and how those behaviors translate into safe, effective dosing regimens — remain to be characterized. Formulation is untested at scale, and scalable production is a genuine obstacle for any RiPP, since fermentation yields, the efficiency of the knot-forming enzymes and downstream purification all require optimization before industrial manufacturing becomes realistic. Resistance surveillance will be essential as well: low spontaneous resistance in the laboratory does not guarantee that resistance will not emerge and spread under the intense selective pressure of clinical drug exposure. And like all early findings, the preclinical results await independent validation by research groups beyond the original discoverers. The review is careful to note that this body of work includes no clinical trial; the road from mouse models to medicine runs through years of further development.

Even with those caveats, the arrival of lariocidin marks a meaningful shift in emphasis for the field. For decades, antibiotic development has largely meant redecorating old scaffolds in a running battle to stay ahead of resistance. Lariocidin offers something different: a new chemical architecture — a self-knotting peptide — aimed at the oldest and most validated target in antibacterial therapy, the ribosome, through a binding site the existing armory does not touch. Whether it ultimately survives the gauntlet of pharmacokinetic testing, manufacturing scale-up and clinical trials remains an open question, and the review avoids promising a new medicine on pharmacy shelves. What it does argue is that genome mining, RiPP bioengineering and ribosome structural biology have matured into a discovery engine capable of surfacing candidates that the classical pipeline overlooked. If that engine keeps running, the knotted molecules hiding in the world’s soil may yet supply the next chapter in humanity’s fight against the superbugs.

For decades, precious metals like platinum and rhodium have been indispensable in the synthesis processes of carbohydrate-based antibiotics. These metals facilitate complex chemical reactions, permitting the assembly of synthetic sugars necessary for the penetration and action against tenacious pathogens, including notorious culprits like Pseudomonas aeruginosa. This bacterium, prevalent in hospital settings, poses a significant threat to immunocompromised patients by resisting multiple drugs available today. However, the reliance on these metals carries significant downsides, including environmentally damaging mining practices, high production costs, and the requirement for harsh catalytic conditions that limit scalability and sustainability.

The recent publication in Nature Communications authored by an OU team led by Professor Indrajeet Sharma eye-opening overturns this paradigm by introducing a method that harnesses either blue light or iron to catalytically drive the synthesis of diazo-thioglycosides—crucial carbohydrate building blocks—without the need for traditional precious metals. By employing visible blue light as an energy source or cost-effective iron salts such as iron (III) triflate (Fe(OTf)3), these researchers achieve iterative and stereoselective glycosylations with remarkable sensitivity and selectivity. This method not only lowers the toxicological footprint of the process but also reduces operational complexities and manufacturing costs, making it highly attractive for pharmaceutical development pipelines.

The underlying chemistry capitalizes on the activation of diazo groups under blue light irradiation or iron catalysis, which facilitates the transfer of thioglycoside donors to target molecules. Unlike earlier approaches that require stringent conditions and expensive catalysts, this light-activated and iron-mediated process operates under mild and metal-sparing environments. The stereochemical control is preserved, ensuring that the resulting carbohydrate structures maintain the precise spatial orientation necessary for biological activity. This is crucial because even minute changes in carbohydrate stereochemistry can lead to profound differences in how antibiotics or pro-drugs interact with bacterial cell walls or human enzymes.

The significance of this approach extends beyond just synthetic convenience. Many antibiotics rely on carbohydrate moieties to traverse the formidable outer membrane of gram-negative bacteria—layers that traditionally obstruct drug entry, rendering several candidates ineffective. By innovating a cleaner, cheaper synthesis route, Sharma’s team potentially opens the door for designing next-generation antibiotics that use carbohydrates as molecular “keys” to breach these bacterial defenses. Such strategies could revive otherwise dormant drug candidates, enhancing their potency and broadening the scope of treatable infections amidst the accelerating global crisis of antimicrobial resistance.

A particularly fascinating facet of this research lies in its application to pro-drug development. Pro-drugs are therapeutics administered in inactive or less active forms that undergo metabolic conversion within the body to release the active compound. Carbohydrates often serve as solubility enhancers, improving a drug’s bioavailability. The OU team is investigating the attachment of specially engineered sugars, including thiosugars—sugar analogs where oxygen atoms are replaced by sulfur—using their blue light-based synthetic method. This chemical modification imparts resistance to enzymatic degradation, potentially allowing these molecules to persist longer in physiological environments and exert sustained therapeutic effects against challenging infections and even cancer.

The innovative use of blue light to drive these reactions, pioneered by lead researcher Surya Pratap Singh under Professor Sharma’s supervision, eliminates dependency on heavy metals that have plagued pharmaceutical synthesis for decades. Blue light, with wavelengths in the visible spectrum, provides a gentle yet effective energy source to activate chemical intermediates selectively without undesirable side reactions or toxicity. This metal-free activation represents a significant leap toward green chemistry principles within medicinal chemistry, reducing hazardous waste and supporting safer pharmaceutical manufacturing protocols.

Collaborations within the University of Oklahoma have further strengthened the translational potential of this work. Partnering with Professor Helen Zgurskaya, whose expertise lies in multidrug resistance mechanisms in Pseudomonas aeruginosa, the team is exploring whether their carbohydrate modifications can enhance the permeability and effectiveness of compounds developed in her lab. Many promising candidates have traditionally failed due to their inability to penetrate the bacterium’s formidable outer lipid membrane; attaching these newly synthesized carbohydrate moieties may unlock their therapeutic potential, reversing drug resistance trends.

As Professor Sharma highlights, drug-resistant infections represent a looming public health emergency expected to escalate without innovation. Synthetic carbohydrate-based antibiotics created via this blue light or iron-mediated glycosylation could be vital tools in this fight. Furthermore, the modularity and adaptability of this approach may allow rapid iteration and tailoring of drug molecules to combat emerging resistance, offering hope for dynamic drug discovery pipelines attuned to evolving microbial threats.

Beyond antibiotics, the enhanced stability and effectiveness of modified carbohydrate drugs may transform cancer treatment modalities. By prolonging drug half-lives and improving solubility, these sugar conjugates can optimize dosing regimens and minimize side effects. The inherent finesse of their synthetic strategy enables precise control over molecular architecture, a critical aspect of designing potent yet safe therapeutic agents.

This research, funded by the National Science Foundation and published in Nature Communications, demonstrates an elegant convergence of synthetic organic chemistry, photochemistry, and biomedical science. The team’s work ushers in a new era where simple, environmentally benign techniques can replace costly, toxic processes, heralding profound shifts in antibiotic and cancer drug design. By leveraging inherently abundant resources like light and iron, this innovation aligns with global sustainability goals and medical imperatives alike, potentially impacting millions of lives.

For readers interested in further details or related research, Professor Indrajeet Sharma’s laboratory website provides extensive resources and publications that delve into advanced drug discovery techniques, including this transformative blue-light-activated glycosylation method. As antibiotic resistance continues to threaten modern medicine, such creative and pragmatic solutions may prove critical in averting a post-antibiotic era.

Subject of Research: Not applicable

Article Title: Fe(OTf)3 or Photosensitizer-free blue lightactivated diazo-thioglycoside donors for Iterative and stereoselective glycosylations

News Publication Date: 21-Apr-2025

Web References:

• https://indrajeetsharma.com/
• https://ou.edu/news/articles/2025/january/how-a-single-nitrogen-atom-could-transform-the-future-of-drug-discovery
• https://www.nature.com/articles/s41467-025-56445-1

References:
Sharma, I., Singh, S.P., Chaudhary, U., Daróczi, A., & Zgurskaya, H. (2025). Fe(OTf)3 or Photosensitizer-Free Blue Light Activated Diazo-Thioglycoside Donors for Iterative and Stereoselective Glycosylations. Nature Communications, DOI: 10.1038/s41467-025-56445-1.

Image Credits: Travis Caperton

Keywords:
Antibiotic resistance, Discovery research, Drug research, Drug resistance, Drug development, Carbohydrates, Cancer treatments